A Case of Enterococcal Patent Ductus Arteriosus-associated Endarteritis in a Preterm Neonate

Pediatr Infect Dis J. 2024 Apr 1;43(4):351-354. doi: 10.1097/INF.0000000000004232. Epub 2024 Jan 18.

Abstract

Introduction: The persistent patency of the ductus arteriosus frequently occurs in premature neonates and can cause infective endocarditis (IE) or ductal endarteritis (DE) during sepsis. Even though neonatal IE and DE are believed to be a rare eventuality, their incidence has been increasing in the last decades due to the improved survival of even more preterm babies, favored by highly invasive procedures and therapies. In parallel, antimicrobial resistance is another rising problem in neonatal intensive care units, which frequently compels to treat infections with broad-spectrum or last generation antibiotics.

Case presentation: We report the case of a preterm neonate affected by patent ductus arteriosus-associated DE that followed an episode of sepsis caused by a high-level aminoglycoside-resistant enterococcus. The neonate was successfully treated with the synergistic combination of ampicillin and cefotaxime.

Discussion: IE and patent ductus arteriosus-associated DE are rising inside neonatal intensive care units and neonatologists should be aware of these conditions. Enterococcal IE and patent ductus arteriosus-associated DE sustained by high-level aminoglycoside-resistant strains can be successfully treated with the synergistic combination of ampicillin and cefotaxime even in preterm neonates.

Publication types

  • Case Reports

MeSH terms

  • Aminoglycosides
  • Ampicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Cefotaxime
  • Ductus Arteriosus, Patent* / complications
  • Ductus Arteriosus, Patent* / drug therapy
  • Endarteritis*
  • Endocarditis*
  • Endocarditis, Bacterial* / diagnosis
  • Endocarditis, Bacterial* / drug therapy
  • Humans
  • Infant, Newborn
  • Sepsis*

Substances

  • Anti-Bacterial Agents
  • Ampicillin
  • Cefotaxime
  • Aminoglycosides